Citations

Mayo Clinic

Clear

1157 citation(s) found for "Báez, Sandra".

Comparison of Blood-conservation Strategies in Cardiac Surgery Patients at High Risk for Bleeding
Nuttall, Gregory A. , Oliver, William C., Ereth, Mark H. , Santrach, Paula J., Bryant, Sandra C. , Orszulak, Thomas A., Schaff, Hartzell V.

Anesthesiology | November 10, 2003 | Volume: 92 | Issue: 3 | Pages: 674-682

10.1097/00000542-200003000-00010 | PMID 10719945 Get It

Background Aprotinin and tranexamic acid are routinely used to reduce bleeding in cardiac surgery. There is a large difference in agent price and perhaps in efficacy. Methods In a prospective, randomized, partially blinded study, 168 cardiac surgery patients at high risk for bleeding received either a full-dose aprotinin infusion, tranexamic acid (10-mg/kg load, 1-mg x kg(-1) x h(-1) infusion), tranexamic acid with pre-cardiopulmonary bypass autologous whole-blood collection (12.5% blood volume) and reinfusion after cardiopulmonary bypass (combined therapy), or saline infusion (placebo group). Results There were complete data in 160 patients. The aprotinin (n = 40) and combined therapy (n = 32) groups (data are median [range]) had similar reductions in blood loss in the first 4 h in the intensive care unit (225 [40-761] and 163 [25-760] ml, respectively; P = 0.014), erythrocyte transfusion requirements in the first 24 h in the intensive care unit (0 [0-3] and 0 [0-3] U, respectively; P = 0.004), and durations of time from end of cardiopulmonary bypass to discharge from the operating room (92 [57-215] and 94 [37, 186] min, respectively; P = 0.01) compared with the placebo group (n = 43). Ten patients in the combined therapy group (30.3%) required transfusion of the autologous blood during cardiopulmonary bypass for anemia. Conclusions The combination therapy of tranexamic acid and intraoperative autologous blood collection provided similar reduction in blood loss and transfusion requirements as aprotinin. Cost analyses revealed that combined therapy and tranexamic acid therapy were the least costly therapies.
Thyrotropin Receptor-DNA Vaccination of Transgenic Mice Expressing HLA-DR3 or HLA-DQ6b
Pichurin, Pavel N. , Pichurina, Oxana, David, Chella S., Rapoport, Basil, McLachlan, Sandra M., Chen, Chun-Rong , Pichurin, Oksana

Thyroid | October 29, 2003 | Volume: 13 | Issue: 10 | Pages: 911-917

10.1089/105072503322511300 | PMID 14611699 Get It

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Fonseca, Rafaël , Debes-Marun, Carina, Picken, Elisa B., Dewald, Gordon W., Bryant, Sandra C. , Winkler, Jerry M., Blood, Emily, Oken, Martin M., Santana-Dávila, Rafael , González-Paz, Natalia, Kyle, Robert A. , Dispenzieri, Angela , Lacy, Martha Q. , Greipp, Philip R., Gertz, Morie A. , Dispenzieri, Angela , Fonseca, Rafael

Blood | June 17, 2003 | Volume: 102 | Issue: 7 | Pages: 2562-2567

10.1182/blood-2003-02-0493 | PMID 12805059 Get It

Abstract Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and near-tetraploid MM. The hypodiploid, pseudodiploid, and near-tetraploid karyotypes can be referred to as the nonhyperdiploid MM. Immunoglobulin heavy-chain (IgH) translocations are seen in 60% of patients. We studied the relation between aneuploidy and IgH translocations in MM. Eighty patients with MM and abnormal metaphases were studied by means of interphase fluorescent in situ hybridization (FISH) to detect IgH translocations. We also studied a second cohort of 199 patients (Eastern Cooperative Oncology Group [ECOG]) for IgH translocations, chromosome 13 monosomy/deletions (Δ13), and ploidy by DNA content. Mayo Clinic patients with abnormal karyotypes and FISH-detected IgH translocation were more likely to be nonhyperdiploid (89% versus 39%, P < .0001). Remarkably, 88% of tested patients with hypodiploidy (16 of 18) and 90% of tested patients with tetraploidy (9 of 10) had an IgH translocation. ECOG patients with IgH translocations were more likely to have nonhyperdiploid MM by DNA content (68% versus 21%, P < .001). This association was seen predominantly in patients with recurrent chromosome partners to the IgH translocation (11q13, 4p16, and 16q23). The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter. (Blood. 2003;102:2562-2567)
Peptide Scanning for Thyrotropin Receptor T-Cell Epitopes in Mice Vaccinated with Naked DNA
Pichurin, Pavel N. , Schwarz-Lauer, Lise, Braley‐Mullen, Helen , Paras, Charmaine, Pichurina, Oxana, Morris, John C., Rapoport, Basil, McLachlan, Sandra M., Pichurin, Oksana

Thyroid | January 6, 2003 | Volume: 12 | Issue: 9 | Pages: 755-764

10.1089/105072502760339316 | PMID 12481940 Get It

Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucα1-2 glycosyltransferase
Thomsson, Kristina A. , Hinojosa-Kurtzberg, Marina, Axelsson, Karin , Domino, Steven E. , Gendler, Sandra , Hansson, Gunnar C. , Lowe, John B.

Biochemical Journal | October 25, 2002 | Volume: 367 | Issue: 3 | Pages: 609-616

10.1042/bj20020371 | PMID 12164788 Get It

In gene-targeted mouse models for cystic fibrosis (CF), the disease is mainly manifested by mucus obstruction in the intestine. To explore the mucus composition, mucins insoluble and soluble in 6M guanidinium chloride were purified by three rounds of isopycnic ultracentrifugation from the small and large intestines of CF mice (Cftrm1UNC/Cftrm1UNC) and compared with wild-type mice. The amino acid composition was typical of that for mucins and showed increased amounts of the insoluble (2.5-fold increase) and soluble (7-fold increase) mucins in the small intestine of the CF mice compared with wild-type mice. Mucins from the large intestine of both wild-type and CF mice showed a high but constant level of fucosylation. In contrast, the insoluble and soluble mucins of the small intestine in CF mice revealed a large increase in fucose, whereas those of wild-type mice contained only small amounts of fucose. This increased fucosylation was analysed by releasing the O-linked oligosaccharides followed by GC-MS. NMR spectroscopy revealed that the increased fucosylation was due to an increased expression of blood group H epitopes (Fucα1-2Gal-). Northern-blot analysis, using a probe for the murine Fucα1-2 fucosyltransferase (Fut2), showed an up-regulation of this mRNA in the small intestine of the CF mice, suggesting that this enzyme is responsible for the observed increase in blood group H-type glycosylation. The reason for this up-regulation could be a direct or indirect effect of a non-functional CF transmembrane conductance regulator (CFTR) caused by the absence of CFTR channel.
Resistant Hypertension
Taler, Sandra J. , Textor, Stephen C., Augustine, J.

Hypertension | July 28, 2002 | Volume: 39 | Issue: 5 | Pages: 982-988

10.1161/01.hyp.0000016176.16042.2f | PMID 12019280 Get It

Although resistant hypertension affects a minority of all hypertensives, this group continues to experience disproportionately high cardiovascular event rates despite newer antihypertensive agents. Hypertension represents an imbalance of hemodynamic forces within the circulation, usually characterized by elevated systemic vascular resistance. We studied the utility of serial hemodynamic parameters in the selection and titration of antihypertensive medication in resistant hypertensive patients using highly reproducible noninvasive measurements by thoracic bioimpedance. Resistant hypertension patients (n=104) were randomized to drug selection based either on serial hemodynamic (HD) measurements and a predefined algorithm or on drug selection directed by a hypertension specialist (SC) in a 3-month intensive treatment program. Blood pressure was lowered by intensified drug therapy in both treatment groups (169±3/87±2 to 139±2/72±1 mm Hg HD versus 173±3/91±2 to 147±2/79±1 mm Hg SC, P <0.01 for systolic and diastolic BP), using similar numbers and intensity of antihypertensive medications. Blood pressures were reduced further for those treated according to hemodynamic measurements, resulting in improved control rates (56% HD versus 33% SC controlled to ≤140/90 mm Hg, P <0.05) and incremental reduction in systemic vascular resistance measurements. Although the number of patients taking diuretics did not differ between groups, final diuretic dosage was higher in the hemodynamic cohort. Our results demonstrate superior blood pressure control using a treatment algorithm and serial hemodynamic measurements compared with clinical judgment alone in a randomized prospective study. Our measurements of thoracic fluid volume support occult volume expansion as a mediator of antihypertensive drug resistance and use of impedance measurements to guide advancing diuretic dose and adjustment of multidrug antihypertensive treatment.
Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
Chen, Dongshu, Kashiwaba, Masahiro , Li, Yongqing , Takeuchi, Hideya , Qu, Hui , Rowse, Gerald J., Gendler, Sandra , Küfe, Donald , Gong, Jianlin , Chen, Ling

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 95 | Issue: 11 | Pages: 6279-6283

10.1073/pnas.95.11.6279 | PMID 9600956 Get It

Immunological unresponsiveness established by the elimination or anergy of self-reactive lymphocyte clones is of importance to immunization against tumor-associated antigens. In this study, we have investigated induction of immunity against the human MUC1 carcinoma-associated antigen in MUC1 transgenic mice unresponsive to MUC1 antigen. Immunization of adult MUC1 transgenic mice with irradiated MUC1-positive tumor cells was unsuccessful in reversing unresponsiveness to MUC1. By contrast, fusions of dendritic cells with MUC1-positive tumor cells induced cellular and humoral immunity against MUC1. Immunization with the dendritic cell fusions that express MUC1 resulted in the rejection of established metastases and no apparent autoimmunity against normal tissues. These findings demonstrate that unresponsiveness to the MUC1 tumor-associated antigen is reversible by immunization with heterokaryons of dendritic cells and MUC1-positive carcinoma cells.